Bevacizumab (Bev) with Chemotherapy, Followed by Bev, in the Treatment of Newly Diagnosed and Platinum-Sensitive Recurrent Ovarian Cancer


Bevacizumab (Bev) with Chemotherapy, Followed by Bev, in the Treatment of Newly Diagnosed and Platinum-Sensitive Recurrent Ovarian Cancer
Slides from presentations at ASCO 2011 and comments from Amit M Oza, MD and David R Spriggs, MD

Aghajanian C et al. OCEANS: A randomized, double-blinded, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). Proc ASCO 2011;Abstract LBA5007.

Dr Oza is Professor of Medicine at the University of Toronto, Co-Director of the Bras Family Drug Development Program and Director of the Cancer Clinical Research Unit at Princess Margaret Hospital in Toronto, Canada.

Dr Spriggs is Head of the Division of Solid Tumor Oncology and Winthrop Rockefeller Chair of Medical Oncology at Memorial Sloan-Kettering Cancer Center in New York, New York.